Crypto investor Will Harbone has launched LongGame, a $40 million venture capital fund dedicated to advancing longevity biotechnology, according to a Dec. 12 statement shared with CryptoSlate. The initiative seeks to revolutionize human health by extending healthy lifespans over three decades through investments in innovative fields like stem cell research, gene editing, and senolytics. LongGame targets early-stage biotech startups with scalable technologies, emphasizing pre-seed and seed investments. Beyond funding, the initiative aims to bridge biotechnology and decentralized science (DeSci), fostering collaboration between traditional life sciences and emerging decentralized technologies. The fund plans to integrate tools like DAOs to streamline drug discovery and encourage patient-driven research. Over the next four years, LongGame intends to strategically allocate its capital while supporting global scalability for its portfolio companies. The leadership team at LongGame includes COO Chloe Northcott, formerly of Geometry, and Special Advisor Sebastian A. Brunemeier, General Partner at Healthspan Capital. Dr. Manish Chamoli, the fund’s chief scientific officer, brings deep expertise in aging biology and longevity research from his tenure at the Buck Institute. This team will collaborate with specialists across various fields in medical science and biotechnology to advance its mission.

Full report : LongGame Fund plans to use blockchain tools like DAOs to bridge the life sciences and decentralized tech, enhancing drug discovery processes.